International Association for the Study of Lung Cancer (IASLC) and Lung Cancer Research Foundation (LCRF) Announce Request for Proposals
Groups Request Proposals for Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers NEW YORK, Jan. 11, 2024 /PRNewswire-PRWeb/ -- The Lung Cancer Research Foundation announced today that, in partnership with the International Association for the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 11, 2024 Category: Pharmaceuticals Tags: NPT Source Type: news
Britain's cancer catastrophe: 8,000 are dying needlessly every year from six lethal types of the disease because of 'abysmal' survival rates that see UK rank among worst in world
For example, Britain ranked 27th out of 29 countries for lung cancer, with just 13.3 per cent of patients still expected to be alive five years after diagnosis. (Source: the Mail online | Health)
Source: the Mail online | Health - January 11, 2024 Category: Consumer Health News Source Type: news
Clinically Relevant Endpoints in Early eNSCLC Trials Clinically Relevant Endpoints in Early eNSCLC Trials
Jamie Chaft, MD, highlights the challenges in using overall survival as a primary endpoint in early-stage non-small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2024 Category: Consumer Health News Tags: None MDAngle Source Type: news
Lung Cancer Screening: Unnecessary for Some Patients? Lung Cancer Screening: Unnecessary for Some Patients?
A new study found higher rates of invasive procedures and complications after annual lung cancer screenings than shown in previous research.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 10, 2024 Category: Cancer & Oncology Tags: Family Medicine/Primary Care Source Type: news
Shaping a Philosophy on Treating Early-Stage Non-Small Cell Lung Cancer Shaping a Philosophy on Treating Early-Stage Non-Small Cell Lung Cancer
Jamie Chaft, MD, reflects on how her mentor, Dr Mark Kris, shaped her approach to treating early-stage non-small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Four Crucial Tips for Early-Career Clinicians Managing Early-Stage Non-Small Cell Lung Cancer Four Crucial Tips for Early-Career Clinicians Managing Early-Stage Non-Small Cell Lung Cancer
Narjust Florez, MD, provides four essential pieces of advice for early-career clinicians when treating early-stage non –small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Doctor shares six red flags that could be symptoms of lung cancer
With lung cancer being one of the most common types of cancer, a doctor has listed symptoms that should warrant a visit to see your GP. (Source: Daily Express - Health)
Source: Daily Express - Health - January 10, 2024 Category: Consumer Health News Source Type: news
Reducing Disparities in the Treatment of Early NSCLC Reducing Disparities in the Treatment of Early NSCLC
Jared Weiss, MD, considers the many causes and forms of treatment disparities in early non-small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Moderate-to-Vigorous Exercise Can Delay Mortality in Inoperable Lung Cancer
MONDAY, Jan. 8, 2024 -- Higher device-measured moderate- to vigorous-intensity physical activity (MVPA) is associated with reduced 12-month mortality in people newly diagnosed with inoperable lung cancer, according to a study published online Nov.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2024 Category: Pharmaceuticals Source Type: news
Baltimore biotech backed by more than $300M in funding names new CEO
The company hopes to provide a cheaper alternative to the standard screening for lung cancer. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 5, 2024 Category: Pharmaceuticals Authors: Matt Hooke Source Type: news
Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung Cancer Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung Cancer
Narjust Florez, MD, reflects on the significant changes in the treatment landscape of early-stage non-small cell lung cancer in recent years.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Lung Cancer CT Screening Can Save Lives, But Study Finds Downsides
WEDNESDAY, Jan. 3, 2024 -- Numerous studies have confirmed that annual lung cancer screening using CT scans does save lives. However, new data has emerged showing that scans often pick up abnormalities that lead to follow-up invasive tests -- and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2024 Category: General Medicine Source Type: news
Study IDs Downstream Procedure, Complication Rates After Lung Cancer Screening
TUESDAY, Jan. 2, 2024 -- For individuals undergoing low-dose computed tomography (LDCT) scans for lung cancer screening (LCS), the rates of downstream procedures and complications are higher than observed in the National Lung Screening Trial (NLST),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2024 Category: Pharmaceuticals Source Type: news
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 -- (Healthcare Sales & Marketing Network) -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune ... Biopharmaceuticals, Oncology, Licensing Allorion Therapeutics, EGFR, non-small cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 2, 2024 Category: Pharmaceuticals Source Type: news
